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ABSTRACT:  
A validated stability indicating thin layer chromatographic (TLC) and liquid chromatography coupled with mass 
spectrometry LC/MS methods were developed to analyze Rivaroxaban and its degradation products. Forced 
degradation studies under stress conditions were carried out in order to establish its stability profile. Stress 
conditions recommended by the international conference on harmonization (ICH) including oxidative, 
photolytic, thermal, acidic, and basic hydrolysis were applied. Rivaroxaban found susceptible to acid and base 
hydrolytic stress conditions. Degradation products were identified isolated and characterized using LC-MS and 
TLC. Three major degradation products were detected, separated and determined and two of them were further 
characterized by NMR spectroscopy and FT-IR.  
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1. INTRODUCTION:  
Rivaroxaban Figure 1, chemically known as (S)-5-
Chloro-N-{2-oxo-3-[4-(3-oxomorpholin-4-yl)phenyl]-
1,3-oxazolidin-5-yl-methyl}thiophen-2-carboxamide, is 
a novel, oral, direct Factor Xa inhibitor developed and 
marketed by Bayer under the brand name Xarelto
®
. It 
was approved for the prevention of venous 
thromboembolism in adult patients after hip or knee 
replacement surgery [1-3]. 
 
 
Figure 1 Structure of the Rivaroxaban [4]. 
Molecular Formula C19H18ClN3O5S 
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Chemical stability of the drugs is a major concern during 
drug development as it impacts the efficacy and safety of 
the drug. Stability testing provides evidence of the 
quality of a drug when exposed to the influence of 
environmental factors such as pH, temperature, humidity 
and light. The data from such studies enables storage 
conditions; re-test periods and shelf lives to be 
established. Stress testing helps to determine the intrinsic 
stability of the molecule by establishing its degradation 
pathways [5, 6]. 
 
 
The stability of Rivaroxaban has been studied by the 
following techniques: ultra performance liquid 
chromatography (UPLC) coupled with a photodiode 
array detector [7, 8], HPLC, TLC Densitometry, First 
derivative and First-derivative ratio spectrophotometry 
[9]. The stability profile of Rivaroxaban under various 
stress conditions has been investigated recently in 
several studies [10-12], nevertheless none of these 
studies included full isolation or identification of the 
degradation products. RP-HPLC coupled with tandem 
mass spectrometry and NMR have been used to 
characterize the degradation products [13] and further 
analytical techniques were used in order to investigate 




the degradation kinetics of Rivaroxaban including 
HPLC, TLC-densitometry, LC/MS/MS and UPLC-Q-
TOF-MS/MS [14,15]. 
 
Since Rivaroxaban is not yet official in any of the 
pharmacopoeia [16-18], and there are only few studies 
dealing with its stability profile, the aim of this research 
was to develop a stability indicating method for 
determination of Rivaroxaban plus an identification, 
isolation and characterization of its degradation products 
(DPs) in order to identify its major degradation 
pathways, by using techniques of LC-MS, TLC-
densitometry, NMR spectroscopy and FT-IR spectral 
data. 
 
2.  MATERIALS AND METHODS: 
2.1. Chemicals and reagents: 
Rivaroxaban standard was purchased from NIFTY 
LABS PVT LTD. APIs were obtained from NIFTY 
LABS PVT LTD, Megafine Pharma (P) Ltd and 
Nanyangpukang Pharmaceutical CO. LTD. HPLC 
acetonitrile, methanol, hydrochloric acid, sodium 
hydroxide, hydrogen peroxide, dimethylsulphoxide-d6 
(DMSO-d6) and Toluene were purchased from SIGMA-
ALDRICH®. HPLC water was obtained by Siemens 
Water Technologies LaboStar and Dimethylsulfoxide 
(DMSO) was obtained from Scharlau. 
 
2.2. Instruments 
The chromatographic analysis was performed with 
SHIMADZU LC-MS prominence system (Shimadzu, 
Japan) provided with UV-Vis Detector SPD 20A, MS 
Detector 2020, two pumps A and B: LC/20AD, column 
oven CTO-20A, manual injector and with Macherey-
Nagel Nucleodur C18 column (250 x 4.6 mm, 5µm 
particle size), System control and data analysis were 
carried out using LabSolutions CS (Schimadzu, Japan). 
KNAUER HPLC Smartline system with PDA detector 
(Germany). TLC aluminum-packed silica gel 60F 254 
plates from Merck (Darmstadt, Germany), Camag TLC 
Scanner II, with computer system and CATS software 





JEKEN Digital Ultrasonic Cleaner. Bechers, Volumetric 
flasks, Micropipettes and Glassware of different volumes 
from Marienfeld Company. Filters PVDF 0.45µm for 
HPLC purchased from TEKNOKROMA. The 
photostability study was carried out in a photostability 
chamber (Sanyo, Leicestershire, UK). The thermal 
stability study was carried out in a dry air oven 
(Memmert, Germany). NMR BRUKER 400 MHz Ultra 
shield TM instrument. FTIR Nicolet 6700 with the 
Detector DTGS Operating software (OMNIC version 7.3 
Thermo Nicolet USA). 
 
2.3. Chromatographic conditions: 
The chromatographic separation was performed on C18 
column (250 x 4.6 mm, 5µm particle size) at a column 
temperature of 55
°
C, The mobile phase A was HPLC 
grade water and the mobile phase B was acetonitrile, the 
gradient program of the mobile phase was set as [Time 
(min)/ Pump B Value (%)] [0.01/15, 15/25, 26/26, 30/40 
and 35/100]. The mobile phase was filtered using 0.45 
µm disposable filter, and degassed by ultrasonic 
vibration prior to use. The flow rate of the mobile phase 
was 1.5 ml/min. The injection volume was 20 µL and the 
detection was carried out at 254nm.Water and 
acetonitrile 10:90 (v/v) was used as a diluent. Stock 
solutions of  Rivaroxaban (2.0 mg/ml) was prepared by 
dissolving 200 mg of Rivaroxaban standard in minimum 
amount of DMSO and made up to volume with diluents 
to obtain a concentration of  2.0 mg/ml. The analysis was 
performed in positive electro-spray ionization mode 
ESI
+
, the ion source voltage was 5000 V, and the source 
temperature was 450 °C, and the curtain gas flow was 15 
psi. This LC-MS method was successfully developed 
and validated as per ICH guidelines and according to 
USP 35 guideline recommendations [18, 19].  
 
2.4. TLC-densitometric assay: 
Pre-coated TLC-plates, silica gel 60 F254 (20 x 20 cm, 
0.25 mm), were used for all determinations. In all 
experiments, bands were spaced 2.0 cm apart and 1.5 cm 
from the bottom edge of the plate. A mobile phase 
composed of Toluene: Methanol: Acetonitrile (50:20:30, 
v/v/v) was used and detection was carried out at 254 nm. 
System suitability criteria were determined in order to 
assess the efficiency of separation. Calibration curve was 
constructed using a standard series covering a 
concentration range 3-10µg/band. Assay validation was 











 and Dept135 NMR spectra were recorded in 
DMSO-d6 at 25°C. The NMR chemical shift values 
were reported on the δ scale in ppm, relative to TMS (δ 
= 0.00) as internal standard. 
 
2.6. FT-IR spectroscopy: 
The IR spectra for Rivaroxaban, and its degradation 
products were recorded in the solid state as KBr 
dispersion, with Range 400-4000nm, the resolution was 
4cm
-1
, scans were 32. 
 
2.7. Degradation protocols: 
The stress conditions employed for degradation studies 
as per ICH recommendation include photolytic, thermal, 
oxidation, and hydrolysis with acid and base. 
Degradation samples were prepared by diluting 
Rivaroxaban stock standard solution in diluents to obtain 
a final concentration of (1mg/ml). The photolytic stress 




study was performed for 7 days at 200 W h/ m
2
 of UV 
light and 1.2 million lux hours of visible light. The 
thermal stress study was performed at 105°C for 7 days. 
The acid, base stress studies were performed with 0.1 N 
HCI for 72h and 0.1 N NaOH for 72 h at room 
temperature. The oxidation stress was done with 3% 
H2O2 solution over a period of 72 h at room temperature. 
All of the stressed samples were quantified against the 
Rivaroxaban reference standard.  Each experiment was 
performed in triplicate. 
 
3. RESULTS: 
3.1. Methods development and validation: 
3.1.1. LC-MS method: 
The main target of the chromatographic method is to 
achieve the separation of degradation products from 
Rivaroxaban after stress conditions employed for 
degradation studies. The described LC-MS method was 
successfully developed and validated as per ICH and 
USP 35 guidelines. It was suitable for the separation of 
Rivaroxaban from most of the other degradation 
products and the retention time for Rivaroxaban was 
25.6 min Figure 2. The degradation products produced in 
the forced degradation were well-separated (Resolution 
> 2.0) from Rivaroxaban, the tailing factor for 
Rivaroxaban was 0.978, and the theoretical plates was 
31115. The method was proved to be linear over the 
calibration range 300-1000µg/ml and the correlation 
coefficient was > 0.999. The method was validated in 
terms of accuracy, precision, repeatability and 
robustness, the percentage recovery values were 99.98%, 
100.13%, 100.09% and 100.12%, respectively and the 
RSD was 0.41. The Detection limits (DL) and 
Quantification limits (QL) were 0.402 and 1.326 μg/ml, 
respectively. 
 
3.1.2. TLC-densitometric method: 
Chromatography was performed on 20 cm × 20 cm thin-
layer chromatographic plates precoated with silica gel 60 
F254. In order to obtain a simple, rapid, reproducible and 
satisfactory resolution and to avoid peak tailing, 
optimization was performed with different mobile phase. 
 
 
Figure 2 Chromatogram of standard solution of Rivaroxaban. 
 
The retention behavior using single non polar toluene 
and polar (methanol, acetonitrile) solvents was 
investigated. Standard and degradation solutions were 
applied 15 mm above the lower edge of the plate. 
Ascending chromatography to a distance of 180 mm was 
performed in the TLC chamber previously saturated for 
20 min. A satisfactory resolution and separation of 
Rivaroxaban and its degradation products was obtained 
with Toluene: Methanol: Acetonitrile (50:20:30, v/v/v). 
After the development, the plates were dried in ambient 
air and the separated zones were scanned in the linear 
reflectance–absorbance mode at 254 nm by means of a 
Camag TLC Scanner II. The peak areas were used for 
quantification. The migration distances of Rivaroxaban 
was 150mm, the recovery of Rivaroxaban ranging from 
98.9 to 102.1%, and the RSD values lower than 2% 
confirms the accuracy of the method. The repeatability 
of the method was assessed by replicate chromatography 
applications (n=6) of Rivaroxaban at the three different 
concentrations. The RSD values obtained from these 
results are lower than 1.5%. The detection limit (DL) 
and the quantification limit (QL) were 0.02 µg/band and 
0.06 µg/band, respectively. 
 
3.2. Degradation of Rivaroxaban:  
Significant degradation of Rivaroxaban was observed in 
acidic and basic hydrolytic stress conditions meanwhile 
it was found stable at neutral hydrolysis, thermolysis, 
photolysis and oxidation. This was consistent with what 
has been reported recently. In total, five DPs were 
observed, two DPs were detected in the solutions 
subjected to acidic hydrolysis and three DPs were 
detected in the solutions subjected to basic hydrolysis, as 
shown in Figure 3 and Table1.The degradation products 













Figure 3 LC-MS Chromatograms of hydrolysis degradation products of Rivaroxaban. 
 
Table 1: Summary of forced degradation studies of Rivaroxaban 











- 99.96 0.03 99.99 - 
Acid hydrolysis (0.1 N HCl) 72 hours 71.834 27.61 99.44 Degradation accompanied by appearance of DP2 and DP3 
Base hydrolysis (0.1 N NaOH) 72hours 63.585 34.83 98.42 Degradation accompanied by appearance of DP1, DP2, 
and DP3 
Neutral hydrolysis 7 days 99.04 0.92 99.96 No degradation occurred 
Oxidation (3% H2O2) 72 hours 99.76 0.08 99.84 No degradation occurred 
Thermal (105° C) 7 days 99.55 0.32 99.87 No degradation occurred 
Photolytic  (UV light) 7 days 99.70 0.09 99.79 No degradation occurred 
Mass balance =  assay %+  sum of all degradants% . 
 
Mass balance (% assay + % total degradation products) 
of all the stressed samples of Rivaroxaban was obtained 
in the range of 98.42–99.96%. As shown in Table 1, loss 
of 28% of Rivaroxaban was observed after 72 hours in 
acidic conditions, while 35% was recorded after 72 
hours in basic conditions. The identification of 
Rivaroxaban and its degradation products was confirmed 
by ESI-MS using scan mode from 50-900 mu to produce 
spectra of molecular weight as shown in Table2. Most 
possible structures were proposed for DPs by comparing 
their fragmentation patterns with that of Rivaroxaban. 
The ESI-MS spectra of Rivaroxaban and DPs are shown 
in Figure 4 
 
Table 2: [M+H]+m/z of Rivaroxaban and its degradation products. 
Stress 
condition 





DP2 21.060 454.05 
Rivaroxaban 25.717 436.05 
DP3 32.490 392.10 
Base 
hydrolysis 
DP1 10.107 410.10 
DP2 21.083 454.05 
Rivaroxaban 25.760 436.10 
DP3 32.193 392.10 
 
 
ESI+-MS spectrum of DP1 
 





ESI+-MS spectrum of DP2 
 
 
ESI+-MS spectrum of DP3 
 
 
ESI+-MS spectrum of Rivaroxaban 
Figure 4 ESI-MS spectrums of Rivaroxaban and its degradation products 
 
Degraded samples were analyzed using TLC Figure 5. 
Bands corresponding to degradation products were 
scratched, extracted using diluent then analyzed using 
LC/MS in order to reveal the identity of each 
degradation product. And as has been previously 
reported, using TLC for preparation and isolation of the 
degradation products presents a simple and economic 
approach when compared to semi-preparative HPLC, 
and the TLC-densitometric analysis results are shown in 
Figure 6. 
 
Figure 5 TLC bands corresponding to hydrolysis degradation products of Rivaroxaban. 





Figure 6 TLC Chromatograms of hydrolysis degradation products of Rivaroxaban. 
 
Dp2 and Dp3 which were isolated by TLC were further 
subjected to NMR and FT-IR studies for structure 
elucidation using conditions mentioned in Materials and 
Methods section. Whereas structural elucidation of DPs 
has been accomplished from NMR, FT-IR and mass 
spectral data. FT-IR spectra of DP2 and DP3 are shown 
















and Dept135 NMR spectra of 




H1NMR of DP2 





C13 NMR of DP2 
 
 
Dept 135  NMR of DP2 
 
 
H1NMR of DP3 
 
 
C13 NMR of DP3 
 
Dept 135 NMR of DP3 




Under influence of various stress conditions as per ICH 
guidelines, Rivaroxaban was more susceptible to 
hydrolysis condition than to the other tested conditions; 
it degraded under stress acid hydrolytic degradation into 
two DPs while under stress base hydrolytic degradation 
three DPs were formed. And as shown in Figure 3 and 
Figure 4 the degradation products DP2 and DP3 were the 
same in the acidic and basic hydrolysis degradation, they 
had identical retention time the same [M+H]
+
in LC 
method and the same Rf in TLC method, which confirms 
that they are the same components. These results were 
proved by NMR and FT-IR spectra. Thus DP2 and DP3 
are hydrolysis degradation products which suggest that 
adding acid to the hydrolysis medium only help to 
accelerate the degradation and increase the formation of 
DP3, while the basic conditions also increase the speed 
of degradation, increase the formation of DP2 and lead 
to formation of DP1, which only appeared in basic 
hydrolysis. Both chromatographic methods were able to 
separate all the degradation products not only from 
Rivaroxaban but also from each other in stressed 
samples. Thus, the methods proved to be selective and 
stability-indicating. The degradation products were 
successfully characterized using mass spectrometry, 
NMR and FT-IR. 
 
DP1, appeared only under basic hydrolysis at retention 
time of 10.1min, with [M+H]
+
 410 m/z and its Rf was 
0.75 in the TLC method, but unfortunately, within the 
applied conditions, DP1 could not be separated in a 
sufficient amount to continue NMR and FT-IR studies. 
Only DP2 and DP3 were isolated by TLC-densitometric 
and analyzed by NMR and FT-IR spectra. 
 
DP2, appeared in both acidic and basic hydrolysis at 
retention time of 21.0min, with [M+H]
+
 454 m/z and its 
Rf was 0.50 in TLC method. And with the aid of the FT-




 and Dept135 spectra it was 
suggested that DP2 has a molecular weight 453 and 
molecular formula C19H20ClN3O6S. It could be seen from 




NMR spectra of DP2 by comparing to Rivaroxaban, that 
there was an increase in protons (two protons). 
Additional protons could be due to –OH and –NH 
formation by the hydrolysis of oxomorpholin ring. FT-IR 
spectrum shows C=O stretching absorptions at 
1738cm
−1
, N-H stretching absorptions at 1647cm
−1
 and 
O-H board stretching absorptions at 
3367cm
−1
.According to that it is suggested that the 
oxomorpholin ring was opened and a carboxylic acid 
derivative was formed. 
 
For DP3, which appeared also in both acidic and basic 
hydrolysis at retention time of 32.5 min, with [M+H]
+ 
392m/z,  its Rf was 0.35 in TLC method. The NMR 
spectra of DP3 shows a decrease in one carbon at 154 δ 
ppm and the protons remain the same as Rivaroxaban. 
Dept135 shows that DP3 has four -CH2 and eight -CH. 
FT-IR spectrum shows an increase in N-H stretching 
absorptions at 3413cm
−1
,additional C-N stretching 
absorptions at 1126cm
−1
and C=C asymmetric stretch at 
(616 and 637)cm
−1
, while there was a clear absorption 
decrease in C=O stretching absorptions at 1738cm
−1
. As 
a result, DP3 could be formed by hydrolysis of 
oxazolidine ring, where its molecular formula is 
C18H18ClN3O3S and molecular weight is 391. 
 
The above results allowed to propose degradation 
pathways of Rivaroxaban, and the schematic 
representations of mechanism of formation of the 
degradation products under hydrolytic stress are shown 
in Figure 9. 
 
 
Figure 9 Proposed degradation pathways of Rivaroxaban. 
 
5. CONCLUSION: 
The forced degradation behavior of Rivaroxaban was 
studied as per ICH prescribed guidelines. Three 
degradation products were formed under stress acid and 
base hydrolytic conditions as detected by LC-MS and 
TLC-densitometer. ESI-MS studies were carried out to 
characterize structures of degradation products. Two of 
them were isolated by TLC and characterized also by 
NMR and FT-IR spectroscopy, and it was possible to 
predict the major degradation mechanisms. A simple, 
rapid and selective stability indicating LC and TLC 
methods have been developed and validated for the 
determination of Rivaroxaban and its degradation 
products. The developed methods were found to be 
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